Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M16-194 risankizumab in pediatric Crohn's disease
jRCT2031240708Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (12 cohorts), sponsored by AbbVie Inc. Primary endpoints: Cmax (maximum observed plasma concentration) - PK Cohorts 1 and 2, Tmax (time to reach Cmax) - PK Cohorts 1 and 2 and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031240708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240708.